▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / BRGX

BRGX — BIOREGENX, INC.

—
OTC · Information Technology · IT Services · CIK 1593184 ·
Last close
$0.01
Market Cap
$7.36M
52W High
$0.01
52W Low
$0.01
ADV30
54,291
Next earnings
—
BioRegenx, Inc. engages in the research, development, and commercialization of dietary supplements, medical devices, software, and contactless diagnostic technologies in the United States and internationally. The company offers DocSun AI engine, which integrates with a ballistocardiograph that detects an individual's heartbeat; TruScan.AI mobile app for additional health indications; VitalWellness app for DNA and epigenetics platform; and Endocalyx Pro, a dietary supplement targeting microvascular capillary health. It also provides MyBodyRx, a supplement; GlycoCheck software and medical devices; hydrogen water products and health and wellness devices, such as pulsed electro-magnetic field devices; StimaWELL and ReLounge electronic muscle stimulation therapy devices; and Findit.com, a social media content management platform. The company sells its products through a direct selling channel to health professionals and research organizations. BioRegenx, Inc. is headquartered in Chattanooga, Tennessee.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 426,175 348,288 -49,764 -26,415 337,070 45,806 4,870,386
Dec 2025 385,641 318,775 -210,658 -1,017,805 410,986 69,383 4,948,240
Sep 2025 507,755 426,397 -8,459 -80,565 1,167,764 46,947 4,814,900
Jun 2025 445,970 352,456 -105,907 -178,345 1,150,558 46,456 4,805,266

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$38,972
Investing CF
$-59,057
Financing CF
$33,098
CapEx
$-9,057
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.00
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-37,115,564
Inventory
$106,931
Receivables
$39,718
ST Investments
—
EBIT TTM
$-1,243,991
Pretax Income TTM
$-1,543,569
Interest Exp TTM
$299,578
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,765,541
EBITDA
$-300,499
Free Cash Flow
$123,537
Enterprise Value
$9,503,541
Total Cash
$45,806
Total Debt
$2,165,372
Shares Out
969,017,081
Trailing EPS
$0.00
Book Value
$-0.01
ROE
—
ROA
-57.4%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 1,854,513 -518,991 -1,543,569 410,986 4,948,240 — 38,972
Dec 2024 2,340,106 -6,550,734 -23,054,017 508,535 3,887,794 — -324,148
Dec 2023 3,411,415 -3,408,834 -3,600,082 865,750 2,937,177 — -1,515,043
Dec 2022 42,159 -78,308 -78,308 59,149 260,691 — -64,652

Peers — same industry

TickerNameMarket CapLastDaily %
YMT Yimutian Inc. $7.11M $1.06 —
IPDN Professional Diversity Network, Inc. $7.09M $0.67 —
BRQL DYNAMIC AEROSPACE SYSTEMS Corp $7.69M $0.26 —
LCFY Locafy Ltd $7.00M $3.89 —
CYCU Cycurion, Inc. $8.01M $0.93 —

News headlines (Yahoo Finance, 1h cache)

BioRegenx, Inc. (OTC: BRGX) Announces Major Corporate Progress, Auditor Transition, Technology Integration, and AI-Driven Strategic Vision
2025-12-09 13:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →